FDA questions effect of abuse-deterrent opioids

June 13, 2017 Julie Miller

Julie Miller, Editor in Chief

FDA aims to gather information to determine whether products with abuse-deterring formulations are having the intended impact.

Previous Article
Federal agents search Sovereign Health

BHE StaffOn Tuesday, federal officials executed search warrants at several California treatment centers ope...

Next Article
SAMHSA: Medication treatment for SUD increases significantly

Julie Miller, Editor in ChiefAccording to SAMHSA’s latest Behavioral Health Barometer, between 2011 and 201...

×

Have Behavioral Health Business updates sent to your inbox today!

First Name
Last Name
Thank you!
Error - something went wrong!